New oral drug trial targets Tough-to-Treat lung cancer mutation
NCT ID NCT07207395
Summary
This study is testing a new oral medication called JBI-802, given alone or with an existing immunotherapy drug (pembrolizumab), for people with advanced non-small cell lung cancer that has a specific genetic change called an STK11 mutation. The main goals are to see if the treatment is safe and if it can shrink tumors or stop them from growing. About 30 participants will take the oral drug daily on a specific schedule, with some also receiving pembrolizumab by IV every three weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Christ Hospital
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.